ELEGEN

Biotechnology Research • San Carlos, California, United States • 51-100 Employees

Company overview

Headquarters	1300 Industrial Rd, San Carlos, California 94070, US
Website	elegenbio.com
Keywords	Molecular Biology, Microfluidics, Biology, Hardware, Engineering, Dna Synthesis, Synthetic Biology, Organic Chemsitry
Founded	2017
Employees	51-100
Socials

Key Contacts at ELEGEN

Matthew Hill

Founder

Galit Meshulam-Simon

Associate Director Of Commercial Applications

Brian Birdi

Director, Automation Engineering

David Dodd

Director Of Chemistry

Kieran Hervold

Associate Director Of Scientific Computing

Harsh Bharucha

Product Owner

Ronisha Solanki Vazir

Associate Director

Michael Junkin

Associate Director Of Fluidics And Integration

Stephen Henderson

Director Of Control Software

ELEGEN Email Formats

ELEGEN uses 5 email formats. The most common is {first initial}.{last name} (e.g., j.doe@elegenbio.com), used 53.9% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@elegenbio.com	53.9%
{first name}.{last name}	john.doe@elegenbio.com	36.8%
{first initial}{last name}	jdoe@elegenbio.com	2.6%
{first initial}.{second initial}{last name}	j.odoe@elegenbio.com	2.6%
{first name}	john@elegenbio.com	2.6%

About ELEGEN

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

ELEGEN revenue & valuation

Annual revenue	$7,785,505
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$25,000,000
Total funding	$35,000,000